IL-7 is produced by stromal cells and is the major lympho-and thymopoietic cytokine. IL-7 induces proliferation and differentiation of immature thymocytes, and protects thymocytes from apoptosis by induction of bcl-2 expression. The regulation of IL-7 production is poorly characterized, although down-regulation by transforming growth factor-␤ (TGF-␤) has been described. We measured the serum levels of IL-7 before and after bone marrow transplant (BMT) in 32 children undergoing BMT for genetic diseases (severe combined immune deficiency (SCID) and thalassemia), aplastic anemia, and acute lymphoblastic and non-lymphoblastic leukemia (ALL and ANLL). Prior to BMT, the highest IL-7 levels were observed in patients with SCID and ALL, ie those patients with genetic or acquired lymphopenia. Patients with thalassemia and ANLL had normal levels of IL-7. Over the 8 weeks following BMT, the IL-7 levels of patients with SCID and ALL fell as the absolute lymphocyte count (ALC) increased. No detectable change in IL-7 levels was observed in the patients with thalassemia and ANLL. Levels of IL-7 were highest in the young infants with SCID compared to the agematched controls. Together, the data demonstrate that serum levels of IL-7 in lymphopenic patients are inversely related to patient age and the absolute lymphocyte count (ALC). The inverse relationship to ALC suggests that there is either direct regulation of stromal production or more likely, binding of secreted IL-7 to lymphocytes expressing IL-7 receptors.
interactions with the microenvironment of the bone marrow and lymphopoietic organs. The ability of the stromal cells to support lymphopoiesis after BMT is adversely affected by age, graft-versus-host disease (GVHD), irradiation, immunosuppressive therapy and infections. However, the recipients of allogeneic BMT who do not have GVHD and recipients of autologous BMT are also immune deficient. [10] [11] [12] [13] [14] [15] [16] There is growing evidence that production of T lymphocytes is dependent upon interleukin-7 (IL-7). IL-7 is a cytokine produced by bone marrow and thymic stroma. IL-7 was originally identified by its ability to induce proliferation of B cell progenitors in vitro and in vivo and was subsequently shown to stimulate T lymphopoiesis. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Recently, we have shown that administration of IL-7 significantly enhances immune recovery in mice after T celldepleted BMT. 27 Therefore, production of IL-7 may be one of the mechanisms regulating de novo production of T lymphocytes after BMT.
In the present study we analyzed serum IL-7 levels by ELISA in patients before and after BMT in relation to the patients' clinical characteristics and absolute lymphocyte count (ALC). We found that lymphopenic patients and patients less than 1 years old had higher levels of serum IL-7. Understanding of the mechanisms of endogenous IL-7 response to lymphopenia may add to understanding of the mechanism of immune reconstitution after BMT and chemotherapy.
Materials and methods

Patients
Normal controls: Sixty-eight samples from controls were tested for serum IL-7 levels. All serum samples were obtained from blood remaining after routine immunologic testing. Blood samples were obtained from infants undergoing open heart surgery for correction of congenital heart disease (n ϭ 13), healthy siblings of patients undergoing BMT, or from BMT donors (n ϭ 55). Seventeen controls less than 1 years old, 21 children older than 1 year, and thirty adults (Ͼ21 years of age) were included in the study. None of the patients with congenital heart disease had DiGeorge syndrome clinically and by fluorescence in situ hybridization for deletion of the DiGeorge syndrome critical region on chromosome 22q11.
BMT recipients: All BMT recipients were patients treated on the BMT unit at Childrens Hospital Los Angeles from 1992 to 1994. Thirty-two BMT patients were included in the study. Five pre-BMT diagnoses were selected for study because they included children of various ages, had either normal lymphocyte counts or had congenital or acquired lymphopenias, and had either received or not received chemotherapy pre-BMT. The diagnostic groups were severe combined immune deficiency (SCID), acute lymphoblastic leukemia (ALL), acute non-lymphoblastic leukemia (ANLL), ␤-thalassemia major (THAL) and aplastic anemia (AA). The diagnosis of SCID was based on history and physical examination, lymphocyte count, immunophenotype, and lack of proliferative responses to mitogens and antigens. The patients with ALL had received multi-agent chemotherapy and were in either first or second remission. ANLL patients were transplanted in first remission after four courses of chemotherapy with dexamethasone, cytosine arabinoside, 6-thioguanine, etoposide and adriamycin (DCTER). 28 The THAL and AA patients had received supportive care with transfusions. One patient with AA had received 10 doses of anti-thymocyte globulin (ATG) before his matched unrelated donor (MUD) BMT.
BMT preparation, source, and post-BMT care: All patients except five received pre-BMT conditioning with busulfan (1 mg/kg p.o. every 6 h for 16 doses total) followed by cyclophosphamide (50 mg/kg i.v. daily for four doses). One patient with SCID received four doses of anti-thymocyte globulin (ATG) before his histocompatible BMT, and did not receive marrow ablative therapy. The preparative regimen for the four patients with AA consisted of total lymphoid irradiation (TLI), cyclophosphamide 50 mg/kg i.v. daily for two doses, and ATG.
GVHD prophylaxis was administered to all patients, except those who received autologous marrow. Recipients of allogeneic marrow, who were less than 10 years of age received methotrexate (MTX) 10 mg/m 2 on days 1, 3, 6 and 11 after BMT, while those greater than 10 years of age received MTX plus cyclosporin A (CsA). Recipients of T cell-depleted marrow were treated with methylprednisolone 2 mg/kg/day from days 5-18 and ATG every other day for 5-7 days from days 5-18. Recipients of matched unrelated donor (MUD) marrow received MTX, CSA, and ATG.
The research protocols for BMT and investigation of immune function in BMT, normal donors, and cardiac surgery patients were approved by the Committee on Clinical Investigations (Institutional Review Board) of the Childrens Hospital Los Angeles.
Blood samples
Blood samples from BMT recipients were drawn at the time of admission to the BMT unit and weekly thereafter. After centrifugation, the serum samples were frozen in duplicate aliquots at Ϫ70°C in order to batch specimens for measurement.
Enzyme-linked immunoabsorbent assay ( ELISA ) for detection of IL-7
The IL-7 concentration in the serum samples was analyzed using a commercially available high sensitivity ELISA-kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. A standard curve was prepared for each plate, plotting OD vs different concentrations of recombinant human IL-7. All standards and samples were tested in duplicate.
Statistical analyses
Mean values and standard deviation were calculated using routine methods. The probability of the differences was determined with Student's t-test, when two groups were analyzed, and with the use of ANOVA and Student-Newman-Keuls multiple-range tests to define the unique subsets within the study, when multiple groups were analyzed. All analyses were carried out at the alpha ϭ 0.05 level of significance. Correlation statistics were based on the calculation of the Pearson correlation coefficient.
Results
Patient characteristics
The patient characteristics are shown in Table 1 . There were seven patients with SCID, 12 with ALL, six with ANLL, three with thalassemia, and four with AA. There were no statistically significant differences between patients with regard to age, sex and race (not shown), except for the SCID patients who were younger than the rest of the patients and were predominantly boys. The mean age of the patients with SCID was 0.53 Ϯ 0.32 years, compared to the mean of 7.0 Ϯ 2.8 years for the rest of the patients. The high proportion of boys in the SCID group was due to the presence of four patients with X-linked SCID. The type of donor cells used was related to the diagnosis: haploidentical, T cell-depleted BMT was only used for the SCID patients, autologous BMT only for the ALL and ANLL patients, and MUD BMT only for the ALL and AA patients.
Normal control Normal absolute lymphocyte count (ALC):
The ALC in the control group ranged from 1176 to 3986 ϫ 10 3 /ml. Higher ALC were observed in children less than 1 year old, compared to older children and adults (2696 Ϯ 698 ϫ 10 3 /ml; 2143 Ϯ 1012 ϫ 10 3 /ml, 1610 Ϯ 837 ϫ 10 3 /ml, respectively).
Normal IL-7 levels:
The serum IL-7 levels were low in all normal adults (2.82 Ϯ 1.3 pg/ml, n ϭ 30) and children over 1 year of age (4.32 Ϯ 3.9 pg/ml, n ϭ 21). However, we observed significantly higher IL-7 levels in infants (Ͻ1 year old) compared to the rest of the normal controls (7.9 Ϯ 4.8 pg/ml, P Ͻ 0.05 (Figure 1 ). There was no statistically significant correlation between the ALC and serum levels of IL-7 in the control group.
BMT patients Absolute lymphocyte count (ALC):
The pre-BMT ALC varied from 20 to 2786 ϫ 10 785 in ANLL, AA and THAL patients than SCID and ALL patients. Patients with SCID had the lowest ALC ( Figure  2 ). The ALC of the patients with ALL was intermediate between those with SCID and those with ANLL, AA, and thalassemia. Lymphopenia was seen in all patients after BMT. The lowest ALC was observed between day 9 and 16. The ALC began to increase by the third week post-BMT, but the patients remained lymphopenic throughout the period of the study (8 weeks after BMT).
IL-7 levels
Pre-transplant IL-7 levels: The pre-transplant levels of IL-7 in the BMT patients was related to the the diagnosis ( Table 2 , Figure 2 ). The highest levels were found in SCID and ALL patients (33 Ϯ 5.2 pg/ml, and 16.5 Ϯ 4.1 pg/ml, respectively). IL-7 levels in SCID patients were significantly higher than in age-matched controls. Lower levels of IL-7 were found pre-transplant in the ANLL (2.8 Ϯ 1.2 pg/ml ), AA (3.12 Ϯ 2.8 pg/ml), and THAL (8.0 Ϯ 1.8 pg/ml) patients. The pre-transplant level of IL-7 in the BMT patients was inversely related to the pre-transplant ALC (r ϭ Ϫ0.38, P Ͻ 0.05).
Post-transplant IL-7 levels:
The levels of IL-7 were measured weekly over the first 8 weeks after BMT ( Table 2 ). The levels of IL-7 throughout the post-BMT period correlated with the pre-transplant levels (r ϭ 0.882, P Ͻ 0.05). When analyzed separately, serum IL-7 levels in patients with SCID and ALL were significantly correlated with the ALC (Figures 3 and 4) . In the SCID and ALL groups, the highest level of serum IL-7 was found at the time of minimal ALC; with the recovery of the ALC, the IL-7 level decreased (r ϭ Ϫ0.432 for ALL, and r ϭ Ϫ0.39 for SCID, P Ͻ 0.05) (Figures 3 and 4) . In the ANLL, AA and THAL patients, no correlation between post-BMT serum IL-7 levels and ALC was observed. In these patients, the serum IL-7 levels were significantly lower than predicted for the Values of IL-7 are expressed as mean Ϯ s.d. SCID ϭ severe combined immunodeficiency; ALL ϭ acute lymphocytic leukemia; ANLL ϭ acute non-lymphocytic leukemia; AA ϭ aplastic anemia; THAL ϭ thalassemia. degree of lymphopenia. In all BMT patients IL-7 levels did not correlate with the incidence of GVHD and type of BMT conditioning regimen (chemotherapy and/or TLI).
Discussion
The present study examined the relationship of serum IL-7 levels to lymphocyte recovery in the early period after clinical BMT. Our results indicate that in younger and lymphopenic patients (SCID and ALL), IL-7 levels were elevated above normal levels and were inversely related to the ALC both pre-and post-BMT. An increase in serum IL-7 levels was also observed in these patients in the first 3 weeks after BMT, which was followed by a decline in the IL-7 levels. In non-lymphopenic patients, (ANLL, AA and THAL), the pre-transplant levels of IL-7 were comparable to those seen in normal controls. However, in these latter groups, there was no correlation between IL-7 levels and ALC post-BMT.
Steady-state levels of IL-7 are most likely determined by the equilibrium between IL-7 production and either consumption of IL-7 by IL-7R-bearing cells and any proteolysis or non-specific uptake. IL-7 is made by stroma from fetal liver, thymus, and bone marrow. The IL-7 producing cell in the mouse thymus is an MHC class II-bearing epithelial cell. 29 The IL-7 promoter sequence has a structure typical of housekeeping genes (no TATAA or CAAT boxes, large number of CpG dinucleotides), and it is not known whether IL-7 gene expression by stromal cells is up-regulated by any external stimuli. 30 Recent data indicate that IL-7 production is negatively regulated by TGF-␤. 31 Studies of mice with GVHD have suggested that IL-7 production may also be down-regulated by IL-1 and interferon-␥ (IFN-␥). 32 IL-7 consumption by IL-7R-bearing cells is probably rapid and extensive. In a previous study of IL-7 administration in a murine model of BMT, IL-7 levels were undetectable within 30 min of i.v. administration of recombinant human IL-7 (E Bolotin, unpublished observations). IL-7R are expressed by nearly all circulating lymphocytes as well as many progenitors. The number of such IL-7R-bearing cells is likely to be decreased in lymphopenic patients, in whom the absolute number of lymphocytes is depressed. In the present study, the patients with SCID were most lymphopenic and thus most likely to have abnormal clearance of IL-7. In addition, the patients with X-SCID in the present study have a specific defect in the ␥c subunit of the IL-7R, making it unlikely that there was any physiologic clearance of IL-7 by receptor-binding in these patients, 33 although slow clearance by low affinity IL-7R could not be ruled out. The patients with ALL were also lymphopenic, which was probably due to exposure to particularly lymphotoxic drugs, eg glucocorticoids, vincristine, and purine nucleosides, used in treatment of ALL. Interestingly, the patients with ANLL were much less lymphopenic than the ALL patients, suggesting that the marrow-suppressive therapy used in ANLL treatment has less effect on mature lymphocytes.
Although direct upregulation of IL-7 production in response to lymphopenia is an attractive hypothesis, we think that it is more likely that the increased IL-7 levels observed in lymphopenic patients, was due to altered consumption.
Previous studies have shown an inverse correlation between serum levels of G-CSF and absolute neutrophil count; 34, 35 serum erythropoietin level and red blood cell count; [36] [37] [38] FLT 3 and blood cell number; 39 and thrombopoietin and megakaryocyte number and platelet count. [40] [41] [42] These inverse relationships between the levels of cytokines and the progeny that develop in response to the cytokines have been thought to represent consumption of ligand by receptor-bearing progenitors or mature cells. By analogy, we propose that binding to IL-7R is a homeostatic mechanism, which regulates circulating IL-7 levels.
An additional determinant of IL-7 levels may be age. We found that among the normal controls, the highest IL-7 levels were found in the infants less than 1 year of age. Furthermore, the highest levels among the patients was in the SCID group, who were the youngest patients in the study. Since there were no infants in the other diagnostic groups, it is not possible to state unequivocally that the high IL-7 levels in the SCID group were due only to their lymphopenia. Previous studies have demonstrated age-dependent declines in thymopoietic capacity in chemotherapy and BMT recipients, beginning in adolescence. 4, 5 It is possible that the high IL-7 levels in infants and lower levels in children and adults in the present study represent one facet of the age-dependent decline in thymic function. Consistent with this hypothesis are studies of marrow stroma from aged mice, which have shown decreased secretion of IL-7 with age. 43 In summary, our data indicate that IL-7 levels are increased in infants and lymphopenic patients, and the levels rise in response to further lymphopenia in the post-BMT period. This is most consistent with IL-7 production being age-dependent, while consumption of IL-7 is related to the number of IL-7R-bearing cells. The latter can be affected by pre-transplant conditions (SCID) or treatment (ALL). The regulation of IL-7 levels by IL-7R binding may be a general mechanism for lymphocyte homeostasis. Further analysis of the relationship between IL-7 levels and longterm reconstitution will be necessary to determine the role of IL-7 in the immune reconstitution after BMT.
